Key result
Beta-blockers fail to reduce death, MI, or heart failure in post-MI patients with LVEF ≥50%.
Why the study?
Does beta-blocker therapy reduce the incidence of death from any cause, myocardial infarction, or heart failure in patients with an LVEF of at least 50% after myocardial infarction?
Does beta-blocker therapy reduce the incidence of death from any cause, myocardial infarction, or heart failure in patients with an LVEF of at least 50% after myocardial infarction?
In patients with normal ejection fraction (LVEF ≥50%) after myocardial infarction, routine beta-blocker therapy does not reduce the composite of all-cause death, MI, or heart failure.
Challenges guideline-endorsed beta-blocker use post-MI with preserved EF; questions prior consensus from older trials.
In this meta-analysis including individual-patient data from five randomized trials, beta-blocker therapy did not reduce the incidence of death from any cause, myocardial infarction, or heart failure in patients with an LVEF of at least 50% after myocardial infarction without other indications for beta-blockers. (Funded by Centro Nacional de Investigaciones Cardiovasculares Carlos III and others; PROSPERO database number, CRD420251119176.).
No takes yet. Share an insight, caveat, or question.
Kristensen et al. (2025) studied this question. Beta-blocker therapy did not reduce all-cause mortality, myocardial infarction, or heart failure in patients with LVEF ≥50% post-myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: